GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ascendis Pharma AS
Ascendis Pharma is a biotechnology company that has developed a unique technology for creating long-acting drugs. Its stock price reflects the commercial success of its drugs and the potential of its platform for developing new products for rare diseases.
Share prices of companies in the market segment - Pharma metabolism
Ascendis Pharma is a biotech company with a unique technology for creating long-acting drugs. We classify it as a metabolomics company. The chart below illustrates the overall dynamics of this sector, where innovative platforms can create significant value.
Broad Market Index - GURU.Markets
Ascendis Pharma is a Danish biotech company that uses its innovative technology to create long-acting drugs. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ASND - Daily change in the company's share price Ascendis Pharma AS
For Ascendis Pharma, which develops long-acting drugs, daily price changes are a measure of their response to trial results. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Ascendis Pharma A/S is a biotech company with a unique platform for developing long-acting drugs. This chart highlights the sector's high volatility. Comparing it to ASND's performance helps assess the extent to which its technology makes it more or less sensitive to overall industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Ascendis Pharma is a Danish biopharmaceutical company developing extended-release drugs for the treatment of rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Ascendis's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company. Its year-over-year performance reflects the commercial success of its drugs and investors' confidence in the potential of its scientific platform aimed at developing new breakthrough drugs, as illustrated by the chart below.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Ascendis Pharma A/S is a Danish biotech company with a unique technology that enables the creation of long-acting drugs. Its focus on rare endocrine diseases has already led to commercial success. The chart below shows how the market perceives the potential of its innovative drug discovery platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ascendis Pharma is a Danish biotech company specializing in the development of long-acting medicines. Its growth is driven by the success of its technology platform and the commercialization of its drugs. It is a growth story driven by science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ascendis Pharma AS
The performance of Ascendis Pharma, a biopharmaceutical company, hinges on the success of its TransCon platform. Monthly fluctuations on the chart reflect sales data for its approved drugs and, more importantly, news about clinical trials of new candidates that could significantly expand the applicability of its technology.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
This chart reflects the dynamics of the biotech sector. For Ascendis, with its innovative drug delivery technology, this is the backdrop. Its outpacing growth compared to the sector demonstrates the commercial success of its drugs and the strength of its scientific platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ascendis Pharma is a Danish biopharmaceutical company with a unique technology for sustained-release drugs. Its performance depends on the success of its drug commercialization and research results. The chart below shows how its innovative platform and company news have enabled its stock to buck the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ascendis Pharma AS
Shares of Ascendis Pharma, a biotech company with a unique drug delivery technology, exhibit high volatility on a weekly basis. News about clinical trials, regulatory decisions regarding its drugs, and sales data create sharp and significant price movements.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Ascendis Pharma shares, like the entire biotech sector, are highly dependent on overall investor risk sentiment. Regulatory news and scientific breakthroughs can boost the entire industry. This chart allows you to compare how a company with a unique technology stacks up against the backdrop of this volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ascendis Pharma is a Danish biotech company with an innovative platform for developing long-acting drugs. Its stock is a growth story driven by science. The chart shows how its development success allows it to move independently of overall market trends.
Market capitalization of the company, segment and market as a whole
ASND - Market capitalization of the company Ascendis Pharma AS
The Ascendis Pharma market capitalization chart represents the financial valuation of an innovative biotech company with a unique, long-acting drug delivery technology. It reflects the success of its hormonal disorders treatments. Its dynamics tell the story of how a scientific platform can create new treatment standards and generate significant value.
ASND - Share of the company's market capitalization Ascendis Pharma AS within the market segment - Pharma metabolism
Ascendis Pharma is a Danish biotech company developing long-acting drugs for the treatment of endocrine and oncological diseases. Its share of its segment's market capitalization reflects the success of its unique TransCon technology. The chart shows its weight among innovators.
Market capitalization of the market segment - Pharma metabolism
Ascendis Pharma is a Danish biopharmaceutical company with an innovative, long-acting drug delivery technology. The chart below shows the overall market capitalization of the sector. Its success in treating growth disorders demonstrates the potential of its platform, which it is now applying to other therapeutic areas.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotechnologies visible on the chart may target rare diseases. Ascendis Pharma has developed a unique technology for creating long-acting drugs. Its market capitalization is based on the success of its drugs and the potential of its platform for developing new treatments.
Book value capitalization of the company, segment and market as a whole
ASND - Book value capitalization of the company Ascendis Pharma AS
For Ascendis Pharma, this graph provides the foundation for developing long-acting drugs. The growth in book value reflects investments in its unique TransCon technology platform and clinical research. This capital is being converted into innovative treatments for rare diseases.
ASND - Share of the company's book capitalization Ascendis Pharma AS within the market segment - Pharma metabolism
Ascendis Pharma develops drugs using its unique TransCon technology. Its share of the sector's assets is determined by its R&D centers and production lines. The chart shows how the company is building a physical base for commercializing its innovative platform.
Market segment balance sheet capitalization - Pharma metabolism
Ascendis Pharma is a biotech company with a unique technology for long-acting drug delivery. Their value lies in their patents and research, not their manufacturing plants. A book value chart highlights their focus on R&D and shows a relatively modest asset base.
Book value of all companies included in the broad market index - GURU.Markets
Ascendis Pharma's balance sheet represents the value of its advanced laboratories and R&D centers, where they developed a unique, long-acting drug delivery technology. The chart shows how the company has grown its scientific and material capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ascendis Pharma AS
Ascendis Pharma owns laboratories. But the market values their unique technological platform, which enables the creation of long-acting drugs. The chart shows how much faith in this technology exceeds the value of their assets.
Market to book capitalization ratio in a market segment - Pharma metabolism
Ascendis Pharma is a biotech company with a unique, long-acting drug delivery technology. Its value lies in this platform and the products based on it. The chart shows a high premium to book value, reflecting investor confidence in its technology.
Market to book capitalization ratio for the market as a whole
Ascendis Pharma is a biotech company with a unique technology platform for developing long-acting drugs. Its market capitalization, compared to the average on this chart, depends almost entirely on the success of its technology. Investors are evaluating the potential of its platform for developing new drugs in various fields of medicine.
Debts of the company, segment and market as a whole
ASND - Company debts Ascendis Pharma AS
Ascendis Pharma, a biotech company with an innovative platform for developing long-acting drugs, uses capital to fund its clinical trials and bring its products to market. This chart shows how the company manages its finances by reinvesting revenue from approved drugs into the development of new candidates in its pipeline.
Market segment debts - Pharma metabolism
Ascendis Pharma is a Danish biotech company with an innovative platform for developing long-acting drugs. Its success depends on its ability to demonstrate the benefits of its technologies in clinical trials. This chart reflects the financial risks the company is taking to create new treatment standards.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ascendis Pharma AS
Ascendis Pharma is a biotech company with a platform for developing long-acting drugs. This chart shows its debt load. Debt can be used to finance clinical trials and bring products to market. Dependence on the success of a few drugs and competition from large pharmaceutical companies are the main risks.
Market segment debt to market segment book capitalization - Pharma metabolism
Ascendis Pharma is a biotech company that has developed a unique technology for creating long-acting drugs. Developing and bringing such drugs to market requires significant investment. The chart shows how aggressively the biotech sector uses debt to fund R&D, and how Ascendis compares to this.
Debt to book value of all companies in the market
Ascendis Pharma is a biotech company with a unique drug delivery technology. The biotech financing model is unique. This chart shows the average debt load of the entire economy. It allows us to assess how Ascendis's financial structure differs from more predictable sectors.
P/E of the company, segment and market as a whole
P/E - Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company that developed the unique TransCon technology, which enables the creation of sustained-release drugs. This chart reflects investor assessments of the platform's potential. High values indicate confidence that the technology can be applied to create better versions of many existing drugs.
P/E of the market segment - Pharma metabolism
Ascendis Pharma is a Danish biotech company with the innovative TransCon platform, which enables the creation of sustained-release drugs. This improves their efficacy and patient convenience. This chart shows the average valuation for the pharmaceutical sector, reflecting the premium investors are willing to pay for breakthrough technology platforms.
P/E of the market as a whole
Ascendis Pharma is a Danish biotech company with a unique technology that enables the creation of long-acting drugs. This chart shows general trends in biotech. ASND's valuation depends on the success of its TransCon platform and its ability to bring new drugs to market, making it less dependent on overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company that developed the unique TransCon technology, which enables the creation of sustained-release drugs. This chart reflects investor confidence in the potential of this platform. Its dynamics reflect the future sales of already approved drugs and the success of clinical trials for new candidates in the pipeline.
%20P%2FE%20Ascendis%20Pharma%20AS&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ascendis-Pharma-AS&v=1772583824780 "Chart of the company's future (projected) P/E Ascendis Pharma AS")
Future (projected) P/E of the market segment - Pharma metabolism
Ascendis Pharma is a biopharmaceutical company using its TransCon technology to develop long-acting drugs. This chart shows the company's estimated future revenue in the context of the biotech sector. It shows whether investors believe its innovative platform can deliver best-in-class treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772583824852 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Ascendis Pharma is a biotech company using its innovative TransCon platform to develop long-acting drugs. Against the backdrop of general market expectations, as this chart illustrates, Ascendis's business operates by the laws of R&D. The success of its drugs in clinical trials and their commercial potential are the primary value drivers, not general economic trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772583824936 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company with a unique technology platform, TransCon, that enables the creation of long-acting drugs. This innovative approach has the potential to improve the treatment of various diseases. This chart shows how the company is transforming its scientific platform into commercially successful drugs.
Profit of companies in the market segment - Pharma metabolism
Ascendis Pharma is a biopharmaceutical company developing innovative therapies using its TransCon technology. This chart shows profitability in the pharmaceutical sector. For ASND, it provides market context, assessing the potential of their platform for developing long-acting drugs for rare diseases.
Overall market profit
Ascendis Pharma is a Danish biotech company with the innovative TransCon platform, which enables the development of drugs with extended release. Its success depends on clinical trial results and regulatory approval. This timeline does not reflect the potential for scientific breakthroughs, which is a key driver for companies like Ascendis.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company with a unique TransCon technology that enables the creation of long-acting drugs. The revenue forecast presented here reflects expectations for sales of its already approved drugs and the success of its R&D pipeline. This is an analyst's view of the potential of its innovative platform.
%20profit%20of%20the%20company%20Ascendis%20Pharma%20AS&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ascendis-Pharma-AS&v=1772583825050 "Graph of future (projected) profit of the company Ascendis Pharma AS")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Ascendis Pharma is a biotech company using its innovative TransCon technology to create long-acting drugs. The profit forecast for this sector depends on the successful application of the platform to various diseases. This chart shows analysts' confidence in the technology's potential to improve existing treatments and create new therapeutic options.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772583825120 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Ascendis Pharma is a biotechnology company developing long-acting drugs for the treatment of rare endocrine diseases. Its success depends on clinical data and regulatory approval. The market profit forecasts presented here influence the overall investment climate in the sector and appetite for innovative biotechnologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772583825162 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ascendis Pharma AS
Ascendis Pharma is a biotech company using its innovative TransCon technology to develop long-acting drugs. This chart shows how investors value its revenue, which currently relies on one approved drug. The high valuation reflects confidence in the potential of the entire technology platform to create new blockbusters.
P/S market segment - Pharma metabolism
Ascendis Pharma is a biotech company using its innovative TransCon technology to develop long-acting drugs for rare endocrine diseases. This chart shows the industry average market capitalization to revenue ratio. It provides an indication of how highly the market values Ascendis's scientific platform and its potential for developing new drugs.
P/S of the market as a whole
Ascendis Pharma is a biotech company using its innovative TransCon technology to create long-acting drugs. Its success depends on the commercialization of its approved drugs and the results of clinical trials. This chart provides a market-wide perspective on investor sentiment toward innovative pharmaceutical platforms and their growth potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ascendis Pharma AS
Ascendis Pharma is a Danish biopharmaceutical company using its TransCon technology to develop long-acting drugs. This chart shows how investors estimate the company's future revenue, reflecting their belief in the potential of its technology to improve the treatment of chronic diseases.
%20P%2FS%20Ascendis%20Pharma%20AS&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ascendis-Pharma-AS&v=1772583825484 "The graph of the company's future (projected) P/S Ascendis Pharma AS")
Future (projected) P/S of the market segment - Pharma metabolism
Ascendis Pharma A/S is a biotech company with a unique technology platform for developing long-acting medications. Its approach is aimed at improving existing treatments. This chart reflects how the market perceives the potential of its technology to create new, more patient-friendly drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772583825517 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Ascendis Pharma is a biotech company using its innovative TransCon technology to create long-acting drugs. Their success depends on the approval and commercialization of their products. This market optimism curve is important for Ascendis. It influences investors' willingness to fund their expensive research and the healthcare system's ability to pay for innovative drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772583825552 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ascendis Pharma AS
Ascendis Pharma is a biotech company that has developed a unique technology for creating long-acting medications. Its first commercial product is designed to treat growth hormone deficiency in children. This chart shows the commercialization of its platform. Revenue growth is directly dependent on successful sales of this drug and progress in the development of other drugs.
Sales of companies in the market segment - Pharma metabolism
Ascendis Pharma is a biotech company that has developed a unique technology, TransCon, which enables the creation of sustained-release drugs. Their first commercial product is designed to treat growth hormone deficiency. This chart shows how revenue from this drug forms the basis for the development of other promising developments.
Overall market sales
Ascendis Pharma is a biopharmaceutical company that developed the innovative TransCon technology, which enables the creation of sustained-release medications. This reduces the frequency of injections for patients with chronic diseases. This total revenue chart includes the healthcare sector, where Ascendis improves patients' quality of life with its technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ascendis Pharma AS
Ascendis Pharma is a biotechnology company using its innovative TransCon technology to develop long-acting drugs. This chart reflects sales expectations, which are primarily driven by the successful launch and growth of its drugs for hormonal and metabolic disorders, particularly growth hormone deficiency.
%20sales%20of%20the%20company%20Ascendis%20Pharma%20AS&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ascendis-Pharma-AS&v=1772583825626 "Schedule of future (projected) sales of the company Ascendis Pharma AS")
Future (projected) sales of companies in the market segment - Pharma metabolism
Ascendis Pharma is a biotech company using its innovative TransCon technology to develop long-acting drugs. This chart shows forecasts for the company's markets, such as growth hormones. It illustrates the potential of these technologies to improve existing treatments, making them more convenient for patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772583825670 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Ascendis Pharma is a biotechnology company developing long-acting treatments for rare diseases. This graph, reflecting the state of the healthcare system and the investment climate, is important to Ascendis. A stable economy ensures funding for expensive treatments and allows the company to attract capital for further research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772583825692 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ascendis Pharma AS
Ascendis Pharma is a biotech company using its TransCon technology to develop long-acting drugs. This chart shows its profitability. Profitability depends on the success of its commercialized products. The ability to create improved versions of existing drugs with more convenient dosing regimens is its key competitive advantage.
Market segment marginality - Pharma metabolism
Ascendis Pharma is a Danish biopharmaceutical company using its innovative TransCon technology to develop long-acting drugs. Profitability depends on the success of their platform and the commercialization of approved drugs. This chart shows their operating results. Their industry outperformance demonstrates the high potential of their unique drug delivery technology.
Market marginality as a whole
Ascendis Pharma is a biotech company with a unique technology that enables the creation of long-acting drugs. Its success depends on clinical data and regulatory approval. This overall profitability chart is not related to Ascendis's scientific platform, which is the primary driver of the company's value.
Employees in the company, segment and market as a whole
Number of employees in the company Ascendis Pharma AS
Ascendis Pharma is a biopharmaceutical company using its innovative TransCon technology platform to create extended-release drugs. This graphic shows a team of scientists working to apply this technology to improve existing treatments in endocrinology and oncology, making therapy more convenient for patients.
Share of the company's employees Ascendis Pharma AS within the market segment - Pharma metabolism
Ascendis Pharma is a Danish biotech company with a unique technology platform, TransCon, enabling the creation of long-acting drugs. This chart demonstrates its scientific potential. It reflects the percentage of scientists and researchers working on innovative drug delivery methods, particularly in endocrinology, that Ascendis attracts.
Number of employees in the market segment - Pharma metabolism
Ascendis Pharma is a Danish biotech company with innovative technology for creating long-acting medications. This approach has the potential to transform the treatment of chronic diseases. This chart shows the growing team of scientists and researchers working on developing next-generation drugs that require less frequent administration, improving patients' quality of life.
Number of employees in the market as a whole
Ascendis Pharma is a Danish biotech company using its innovative TransCon technology to develop extended-release drugs. The company's success depends on the approval and adoption of its drugs. A healthy economy, reflected in this graph through employment, ensures stable funding for healthcare systems, allowing them to cover the costs of new, more patient-friendly treatments from Ascendis.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ascendis Pharma AS (ASND)
Ascendis Pharma is a biopharmaceutical company with a unique drug delivery technology. This chart illustrates a business driven by innovation. Its very high market capitalization per employee indicates that the market highly values its technological platform and the potential of the drugs based on it, which are being developed by an elite team of scientists.
%20of%20the%20company%20Ascendis%20Pharma%20AS%20(ASND)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ascendis-Pharma-AS-ASND&v=1772583825903 "Chart of market capitalization per employee (in thousands of dollars) of the company Ascendis Pharma AS (ASND)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Ascendis Pharma (ASND) is a biotech company with a unique TransCon technology platform that enables the creation of long-acting drugs. The company's value lies in its R&D platform. This chart shows the industry average and illustrates the high market value that innovative, proprietary technology can generate per scientist.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772583825926 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Ascendis Pharma is a biotech company using its unique TransCon technology to create long-acting drugs. In biotech, this metric reflects the value of a platform technology. It demonstrates that its innovative approach can be applied to the development of multiple drugs, creating enormous potential value per scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772583825961 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ascendis Pharma AS (ASND)
Ascendis Pharma is a biotech company with a unique "TransCon" technology, which enables the creation of long-acting drugs. This graph shows how their R&D platform is beginning to generate revenue. The successful launch of one or two drugs allows a small team of scientists and commercial engineers to achieve high profitability.
%20Chart%20Ascendis%20Pharma%20AS%20(ASND)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ascendis-Pharma-AS-ASND&v=1772583826011 "Company Profit Per Employee (in thousands of dollars) Chart Ascendis Pharma AS (ASND)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Ascendis Pharma (ASND) is a Danish biotech company with a platform for developing long-acting drugs. This chart shows the benchmark for "Pharma Metabolism" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is an "R&D business," where a single patent (platform) generates billions.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772583826130 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Ascendis Pharma is a biopharmaceutical company using its TransCon technology to develop long-acting drugs. This productivity profile demonstrates the research-intensive nature of their business. The innovative platform created by their team of scientists enables them to improve existing treatments, creating products with high value and potential for profitability.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772583826137 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ascendis Pharma AS (ASND)
Ascendis Pharma is a biotech company that developed the unique TransCon technology for creating long-acting drugs. This chart illustrates how this innovative platform can generate value. High revenue per employee is a result of the commercialization of the first successful drugs and the potential of the technology to create new drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ascendis-Pharma-AS-ASND&v=1772583826160 "Sales chart per company employee Ascendis Pharma AS (ASND)")
Sales per employee in the market segment - Pharma metabolism
Ascendis Pharma (ASND) is a biotech company with a unique technology for sustained-release drugs. They have a successful drug (growth hormone). This chart shows how efficient their R&D platform is. It compares how their team (scientists, commercial team) generates revenue per employee compared to other biotech companies.
Sales per employee for the market as a whole
Ascendis Pharma is a Danish biotech company with a unique "TransCon" technology that enables the creation of long-acting drugs. Their core business is R&D. This chart shows how their team of scientists creates and brings high-margin, innovative drugs to market, generating high revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Ascendis Pharma AS (ASND)
Ascendis Pharma (ASND) is a Danish biotech company with a unique TransCon technology that enables the creation of long-acting drugs. This chart measures bearish bets. The rise in shorts may reflect investor concerns about the commercial success of their already approved drugs or the high bar for success for their drugs in development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ascendis-Pharma-AS-ASND&v=1772583826283 "Short Shares Chart for the Company Ascendis Pharma AS (ASND)")
Shares shorted by market segment - Pharma metabolism
Ascendis Pharma (ASND) is a biotech company using its TransCon platform to develop long-acting drugs, primarily in endocrinology. This chart illustrates the general skepticism in the biotech sector. It summarizes downside bets, reflecting investor concerns about the commercial success of their drugs.
Shares shorted by the overall market
Ascendis Pharma (ASND) is a Danish biotech with a unique TransCon platform that enables the creation of long-acting drugs. This chart shows the overall level of market fear. When pessimism rises, investors typically avoid biotechs. However, ASND already has approved drugs and revenue, making it more resilient to capital droughts than early-stage companies.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ascendis Pharma AS (ASND)
Ascendis Pharma is a biotech company with a unique "slow-release" technology (TransCon), which allows for less frequent injections. They have already achieved success with growth hormones. The chart shows when the market (above 70) is "overheated" by expectations for the success of their new drugs, or (below 30) "oversold" on news of delays or competitive threats.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ascendis-Pharma-AS-ASND&v=1772583826475 "RSI 14 indicator chart for the company's stock Ascendis Pharma AS (ASND)")
RSI 14 Market Segment - Pharma metabolism
Ascendis Pharma is a biotech company that developed the TransCon platform, which enables the creation of long-acting drugs. They focus on endocrinology (e.g., growth hormone) and oncology. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views platform companies overall and whether the sector as a whole is overheated.
RSI 14 for the overall market
Ascendis Pharma is a Danish biotech company with a unique TransCon platform, enabling the creation of long-acting drugs. They focus on endocrinology and oncology. This market sentiment indicator reflects the appetite for biotech. During periods of euphoria (high values), investors are willing to highly value technology platforms like ASND. During periods of panic, the sector suffers from a lack of funding.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ASND (Ascendis Pharma AS)
Ascendis Pharma is a biotech company using its TransCon platform to develop long-acting drugs, primarily in endocrinology. This chart shows the average target price. Analysts base their forecasts on clinical trial data for new drugs, the speed of commercial launches of already approved drugs, and the potential of their platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ASND-Ascendis-Pharma-AS&v=1772583826652 "A chart showing analyst consensus forecasts for the expected stock price. ASND (Ascendis Pharma AS)")
The difference between the consensus estimate and the actual stock price ASND (Ascendis Pharma AS)
Ascendis Pharma is a biotech company that developed TransCon technology (sustained drug release). The company focuses on endocrinology. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in Ascendis's technology platform and R&D pipeline, seeing potential in them.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ASND-Ascendis-Pharma-AS&v=1772583826670 "A chart showing the difference between the consensus forecast and the actual stock price. ASND (Ascendis Pharma AS)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Ascendis Pharma is a Danish biotech company that developed the unique "TransCon" technology, which enables the creation of sustained-release drugs. This chart shows analysts' overall expectations across the pharmaceutical sector, reflecting whether experts believe in the success of this innovative platform.
Analysts' consensus forecast for the overall market share price
Ascendis Pharma is a Danish biotech company with a unique technology for sustained-release drugs. It is an R&D company. Overall market sentiment, visible on this chart, influences risk appetite. During periods of optimism, investors are willing to finance Ascendis's expensive developments. During downturns, biotech companies find it more difficult to attract capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ascendis Pharma AS
Ascendis Pharma is a Danish biotech company unique in its TransCon technology, which enables the creation of extended-release drugs. This chart is an assessment of their platform. It reflects the commercial success of their first drug (for growth hormone deficiency) and the market's confidence that their technology can improve other existing drugs.
AKIMA Market Segment Index - Pharma metabolism
Ascendis Pharma is a Danish biotech company that has developed a unique extended-release technology (TransCon), transforming daily growth hormone injections into weekly ones. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Ascendis's innovative platform (TransCon) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Ascendis Pharma is a Danish biotech company that has developed a unique technology (TransCon) for creating long-acting drugs. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story, rooted in the principles of biotech, compares to general economic trends that influence investor risk appetite.
